middle.news
Pathkey.AI Advances AI Chip Design and Clinical Trial Platforms Amid FY26 Loss
4:52pm on Monday 31st of August, 2026 AEST
•
Technology
Read Story
Pathkey.AI Advances AI Chip Design and Clinical Trial Platforms Amid FY26 Loss
4:52pm on Monday 31st of August, 2026 AEST
Key Points
FY26 net loss of $3.65 million, revenue of $47,632
Completed $36.7 million asset acquisition of Chipforge Pte Ltd
Chipforge produced FPGA-capable designs, targeting FY27 commercial rollout
TrialKey platform development and marketing advanced for broader adoption
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pathkey.AI (ASX:PKY)
OPEN ARTICLE